05/07/2026
A groundbreaking gene therapy has successfully reversed deafness in all participants of a clinical trial who had a specific genetic mutation. The therapy targets deafness caused by mutations in the OTOF gene, which is responsible for producing a protein essential for transmitting sound signals to the brain.
A single injection of a harmless virus carrying a healthy copy of the OTOF gene restored hearing in all ten patients, with improvements seen within weeks and significant restoration within six months. The younger participants showed the most dramatic results, with one child regaining almost all of their hearing.
This success marks a major advancement in the genetic treatment of hearing loss. While this particular therapy addresses a rare form of deafness, the positive results open the door for developing similar gene therapies for other more common causes of genetic hearing loss.